Kelix Bio Acquires Chemi Pharma’s Injectable Oncology Facility

Deal Struck For Maltese Plant As Company Targets Emerging Markets

Kelix Bio has acquired Chemi Pharma’s injectables manufacturing facility in Malta as part of its efforts to improve access to generic oncology therapies across global emerging markets. Kelix has manufacturing operations in India, Egypt and Malta and markets its products in over 40 countries across Africa, Asia and Latin America.

Made in Malta
Kelix Bio acquires oncology manufacturing facility based in Malta • Source: Alamy

Kelix Bio, a specialty generics company focused on emerging markets, has announced a deal to acquire Chemi Pharma’s injectable oncology manufacturing business in Malta, as part of efforts to “further enhance Kelix Bio’s strategy of improving access to oncology therapies across global emerging markets.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business